Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | HCID 73297121 | HCID 73297121 | — |
| Solvent | Tetrahydrofuran | HCID 8028 | — |
| Product | Iberdomide | HCID 67335295 | — |
Reaction Steps
Initially the eeeu was evaluated using (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione freebase and its corresponding anhydrous freebase racemic compound in acetonitrile at 22° C., and was found to be was unfavorably high (94.7%). A hydrated form of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione freebase was subsequently obtained, and the eeeu of the (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrate with its corresponding hydrate racemic compound at 22° C. remained unfavorably high (89.2%). A THF solvate of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione was also obtained, and the eeeu of the solvate with its corresponding anhydrate racemic compound at 22° C. was improved (68.5%). However, a THF solvate of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione is not a suitable drug substance due to the toxicity of THF, and so an alternative approach was sought.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US09309220B2 |
|---|
| Source dataset | uspto-grants-2016_04 |
|---|
| ORD ID | ord-331d320561614a3281f5a718923a7c2b |
|---|
| Source note | uspto-grants-2016_04 |
|---|